Streamlining Specialty Drug Prior Auth in North Carolina

Klivira automates specialty drug prior auth in North Carolina, addressing the complexities of high-cost therapies across both medical and pharmacy benefits for clinics and health systems.

Navigating specialty drug prior authorization presents significant operational hurdles, particularly in dynamic healthcare environments like North Carolina. The intricate distinctions between medical and pharmacy benefits, coupled with evolving payer policies, demand a robust and automated solution to ensure timely patient access to critical medications.

The Nuances of Specialty Drug Prior Auth in North Carolina

Providers in North Carolina, like those nationwide, face the critical challenge of determining whether a prescribed specialty drug falls under the medical or pharmacy benefit. This initial classification dictates the entire prior authorization pathway, impacting submission channels, required documentation, and ultimately, time-to-therapy for biologics, infused agents, and other high-cost therapies.

Common Operational Hurdles in Specialty Drug PA Workflows

Without automation, specialty drug prior authorization workflows are prone to specific failure modes that delay care and consume staff resources. These include misclassifying the drug's benefit side, failing to adhere to payer-specific site-of-care policies, and inadequate documentation of step-therapy requirements or prior-line therapies.

Key Challenges in Specialty Drug Prior Authorization

**Benefit-Side Misclassification**: Incorrectly routing a specialty drug PA to the medical or pharmacy channel.
**Site-of-Care Policy Violations**: Submitting for a site of care that conflicts with payer requirements, leading to denials.
**Step-Therapy Documentation Gaps**: Insufficiently documenting prior-line therapies required for biologic approvals.
**Specialty Pharmacy Fulfillment Delays**: Bottlenecks in coordinating medication delivery after PA approval.

Klivira's Automated Solution for North Carolina Providers

Klivira’s platform streamlines specialty drug prior auth processes, offering automated benefit-side determination per drug, per payer, and per patient context. This ensures accurate routing through appropriate channels, whether via NCPDP SCRIPT ePA for pharmacy benefits or X12 278 and Da Vinci PAS for medical benefits.

Leveraging Industry Standards for Efficient PA Submissions

For pharmacy-benefit specialty drugs, Klivira integrates with established ePA partners such as CoverMyMeds and Surescripts, utilizing the NCPDP SCRIPT ePA standard for efficient submissions. For medical-benefit drugs, our system supports direct payer portal submissions, X12 278 EDI, and the emerging Da Vinci PAS standard, ensuring comprehensive connectivity across the payer landscape.

Optimizing Site-of-Care and Step-Therapy Compliance

Klivira's policy engine incorporates site-of-care logic, identifying and surfacing payer requirements to ensure PA submissions align with policy and avoid unnecessary denials. Furthermore, the platform automates the capture of medication history and treatment response data from FHIR MedicationRequest and Observation resources to accurately document step-therapy compliance.

Coordinated Specialty Pharmacy Handoff

Beyond approval, Klivira coordinates the post-approval specialty pharmacy fulfillment workflow for pharmacy-benefit drugs, reducing handoff delays. While Klivira identifies manufacturer copay-assistance program availability, organizations must discuss the nuanced interaction of these programs with their compliance team, particularly for Medicare patients.

Frequently asked questions

How does Klivira address the medical versus pharmacy benefit distinction for specialty drugs in North Carolina?

Klivira's policy engine automatically determines whether a specialty drug falls under the medical or pharmacy benefit based on the specific drug, payer, and patient context. This ensures that prior authorization requests are routed to the correct channel, preventing benefit-side misclassification.

What industry standards does Klivira utilize for specialty drug PA submissions?

Klivira supports a range of industry standards, including NCPDP SCRIPT for pharmacy ePA, FHIR MedicationRequest for clinical data exchange, Da Vinci PAS for medical-benefit prior authorization, and X12 278 for traditional EDI medical PA submissions. This multi-channel approach ensures broad payer connectivity.

Can Klivira help with site-of-care policy compliance for specialty infusions?

Yes, Klivira's platform includes site-of-care logic that aligns PA submissions with payer policies. It can surface requirements for alternative sites of care (e.g., infusion centers over hospital outpatient departments) before submission, helping to prevent denials related to site-of-care mismatches.

How does Klivira streamline documentation for step-therapy requirements?

Klivira automates the capture of essential clinical documentation for step-therapy. By reading medication history and treatment response data from FHIR MedicationRequest and Observation resources, the platform ensures that prior-line therapy information is accurately populated and included in the PA submission.

Does Klivira manage specialty pharmacy fulfillment directly?

Klivira coordinates the post-approval specialty pharmacy fulfillment workflow for pharmacy-benefit drugs. While it streamlines the handoff process to reduce delays, the platform focuses on the prior authorization process itself rather than direct medication dispensing or logistics.

What are the common failure modes Klivira addresses in specialty drug PA?

Klivira directly addresses critical failure modes such as benefit-side misclassification, site-of-care policy violations, and step-therapy documentation gaps. By automating these complex steps, the platform helps reduce manual errors and accelerates the prior authorization lifecycle for specialty drugs.